Safety, Dose, and Timing of Reteplase in Treating Occluded Central Venous Catheters in Children with Cancer

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 11, 2003, Pages 864-867

  Terrill, Kelly R ^a,c   Lemons, Richard S ^b   Goldsby, Robert E ^b  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Central venous catheter; Pediatric; Reteplase

Indexed keywords

ALTEPLASE; RETEPLASE; UROKINASE;

ADOLESCENT; ARTICLE; BLOOD CLOT LYSIS; CENTRAL VENOUS CATHETER; CHILDHOOD CANCER; CLINICAL ARTICLE; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; OCCLUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT FAILURE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; STERILIZATION; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0242693182     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200311000-00008     Document Type: Article

References (15)

1. Department of Health and Human Services. Important drug warning to health care providers. Bethesda, MD: United States Food and Drug Administration, Jan. 25, 1999.
2. Department of Health and Human Services. Warning letter to Abbott Laboratories. Bethesda, MD: United States Food and Drug Administration, March 19, 199.
3. Atkinson JB, Bagnall HA, Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. JPEN. 1990;14:310-311.
4. Choi M, Massicotte P, Marzinotto V, et al. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort. J. Pediatr. 2001;139:152-156.
5. Hooke C. Recombinant tissue plasminogen activator for central venous access device occlusion. J Pediatr Oncol Nurs. 2000;17:174-178.
6. Ponec D, Irwin D, Hill PA, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices. J Vasc Interv Radiol. 2001;12:951-955.
7. Shen V, Li X, Murdock M, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol. 2003;25:38-45.
8. Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy ofalteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol. 2001;20:317-324.
9. Chesler L, Feusner JH. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol. 2002;24:653-656.
10. Noble S, McTavish D. Reteplase: a review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs. 1996;52:589-605.
11. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891-898.
12. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995;346:329-336.
13. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compare with alteplase infusion in acute myocardial infarction. Circulation. 1995;91:2725-2732.
14. Owens LD. Reteplase for clearance of occluded venous catheters. Am J Health Syst Pharm. 2002;59:1638-1640.
15. Centocor, Inc. Memorandum regarding the stability of reconstituted Retavase after 6 freeze/thaw cycles and storage at -8° C in syringes. Malvern, PA, October 1999.